Abstract

GLP-1 Receptors Agonists are currently FDA approved for managing type 2 diabetes as these medications have been shown to slow gastric emptying, reduce appetite, and increase feelings of fullness. Polycystic Ovarian Syndrome (PCOS) is a pathology affecting women that can result in reduced infertility, menstrual cycle disturbances, insulin resistance, obesity, and cardiovascular problems. Given the significance of metabolic disturbance in women with PCOS, GLP-1 Receptor Agonists have been proposed as a potential therapy that may improve measurable health outcomes and quality of life. By performing a scoping review and analyzing current scientific literature, we sought to elucidate physiological and clinical outcomes of GLP1 RA use for weight loss in women diagnosed with PCOS.